Former Pfizer statistical programming lead Bruno Coelho was indicted in early 2024 for an alleged insider trading scheme involving confidential Paxlovid clinical trial data. Coelho allegedly generated over $215,000 in profits by purchasing Pfizer call options after accessing non-public, high-effectiveness data, leading to charges of securities and wire fraud in the Southern District of New York.